SCHEMBL13657209

SCHEMBL13657209

CS(=O)(=O)c1ccc(O)c(N=O)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 2/20 0.47
LMNA P02545 1/20 0.40
SERPINE1 P05121 2/20 0.39
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
G6PD P11413 1/20 0.38
IDE P14735 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
AKR1C3 P42330 1/20 0.38
MAPT P10636 2/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37
CDK1 P06493 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14028112 0.82 CA2 (0.57) LMNACA1CA2MAPTALDH1A1
SCHEMBL11329269 0.82 HSD17B10 (0.55) LMNASERPINE1CA1CA2MAPT
SCHEMBL28202113 0.81 TDP1 (0.44) LMNASMN1; SMN2MAPTALDH1A1GAA
SCHEMBL27903840 0.78 PTGS2 (0.40) ENPP2LMNAG6PDIDESMN1; SMN2
SCHEMBL5020928 0.77 SERPINE1 (0.61) ENPP2LMNASERPINE1CA1CA2
SCHEMBL14146435 0.77 PTGS2 (0.43) G6PDIDESMN1; SMN2
SCHEMBL28211358 0.77 LMNA (0.51) LMNAG6PDIDESMN1; SMN2MAPT
SCHEMBL19266099 0.77 LMNA (0.56) ENPP2LMNAAKR1C3MAPTALDH1A1
SCHEMBL647314 0.76 FTO (0.59) CA1CA2MAPTGAACDK1
SCHEMBL647313 0.76 FTO (0.59) CA1CA2MAPTGAACDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090246211-A1 Molecular constructs suitable for targeted conjugates TAPESTRY PHARMACEUTICALS, INC. 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090246211-A1 Molecular constructs suitable for targeted conjugates MRPL21, QSOX1, MLX ENPP2 1912/4885LMNA 1851/4885SERPINE1 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.